The thalidomide-dexamethasone regimen can lower VEGF levels and extravascular volume overload (14), but studies indicate that thalidomide carries the risk of escalating peripheral neuropathy, thereby limiting this regimen’s clinical application (15). This evidence concerns the gene VEGFA and peripheral neuropathy.